Dopamine News and Research

Latest Dopamine News and Research

Unique vaccine produces long-lasting anti-cocaine immunity in mice

Researchers from The Scripps Research Institute, Weill Cornell Medical College, and Cornell University have produced a long-lasting anti-cocaine immunity in mice by giving them a unique vaccine that combines bits of the common cold virus with a particle that mimics cocaine.

5 Jan 2011

Researchers develop unique vaccine that produces long-lasting anti-cocaine immunity in mice

5 Jan 2011

Whites with mutations more likely to be susceptible to cocaine abuse

Nearly one in five whites could carry a genetic variant that substantially increases their odds of being susceptible to severe cocaine abuse, according to new research.

21 Dec 2010

Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly

Ipsen announced today that the preliminary data from the ongoing phase IIb study in patients with acromegaly for its chimeric compound BIM 23A760 does not meet the expected inhibition of growth hormone (GH) and IGF-1 levels after repeat dosing. Preliminary phase IIb data showed a strong dopaminergic activity but only weak evidence of somatostatinergic activity.

15 Dec 2010

Research sheds new light on dopamine's role in brain's reward system

Researchers have shed new light on dopamine's role in the brain's reward system, which could provide insight into impulse control problems associated with addiction and a number of psychiatric disorders.

9 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

9 Dec 2010

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.

9 Dec 2010

Drug prescribed for Parkinson's disease may also treat restless leg syndrome: MCG researchers

A drug prescribed for Parkinson's disease may also treat restless leg syndrome without the adverse side effects of current therapies, Medical College of Georgia researchers say.

7 Dec 2010

Genes linked to one-night stands and acts of infidelity

So, he or she has cheated on you for the umpteenth time and their only excuse is: "I just can't help it." According to researchers at Binghamton University, they may be right. The propensity for infidelity could very well be in their DNA.

1 Dec 2010

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

Nearly three-quarters of patients with Parkinson's disease experience fatigue or excessive daytime sleepiness (EDS), but clinicians should assess both problems separately in order to improve the profession's understanding of their distinct, but overlapping, physiology. That is the key finding of a study published in the December issue of the European Journal of Neurology.

1 Dec 2010

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Neuroscientists using a new brain imaging technique could see an investigational drug for Parkinson's disease get into a patient's brain and affect blood flow in several key structures, an indicator the drug may be effective.

1 Dec 2010

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.

30 Nov 2010

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

Neuroscientists at the Centre for Addiction and Mental Health (CAMH) have developed a protein peptide that may be a novel type of highly targeted treatment for depression with a low side-effect profile. Depression affects one in ten Canadians at some time in their lives and is a leading cause of disability worldwide.

30 Nov 2010

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

XenoPort, Inc. announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to support a preclinical study of the efficacy and safety of a novel, orally administered prodrug of acamprosate in reducing L-Dopa induced dyskinesias (LID) in a pre-clinical model of Parkinson's disease.

24 Nov 2010

Parkinson Society Canada awards Quebec scientists $573,384 for research

Quebec Parkinson researchers receive a record $573,384 in funding from Parkinson Society Canada to increase their efforts to identify the causes of this degenerative brain disease for which there is currently no cure. At a Research Innovation event in Montreal this evening, hosted by Parkinson Society Quebec in partnership with McGill University and the CHUM, 11 Parkinson scientists will be lauded for their efforts in getting closer to a cure.

23 Nov 2010

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Dopamine News and Research

Latest Dopamine News and Research

Unique vaccine produces long-lasting anti-cocaine immunity in mice

Researchers develop unique vaccine that produces long-lasting anti-cocaine immunity in mice

Whites with mutations more likely to be susceptible to cocaine abuse

Ipsen discontinues development of chimeric compound BIM 23A760 for acromegaly

Research sheds new light on dopamine's role in brain's reward system

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Euthymics announces EB-1010 Phase II data for major depressive disorder at ACNP meeting

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Drug prescribed for Parkinson's disease may also treat restless leg syndrome: MCG researchers

Genes linked to one-night stands and acts of infidelity

Clinicians should assess sleep-wake disturbances to understand physiology of Parkinson's disease

New brain imaging technique can trace effects of SYN115 drug in Parkinson's disease

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

CAMH neuroscientists develop novel protein peptide for targeted treatment of depression

XenoPort receives grant from Michael J. Fox Foundation to support Parkinson's disease therapies

Parkinson Society Canada awards Quebec scientists $573,384 for research

Scientists solve receptor structure that responds to neurotransmitter dopamine

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Dopamine News and Research

Latest Dopamine News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in